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PeptidesThe extracellular matrix (ECM) of tissues is an assembly of insoluble macromolecules that speciﬁcally interact
with soluble bioactivemolecules and regulate their distribution and availability to cells. Recapitulating this ability
has been an important target in controlled growth factor delivery strategies for tissue regeneration and requires
the design ofmultifunctional carriers. This reviewdescribes the integration of supramolecular interactions on the
design of delivery strategies that encompass self-assembling and engineered afﬁnity components to construct
advanced biomimetic carriers for growth factor delivery. Several glycan- and peptide-based self-assemblies re-
ported in the literature are highlighted and commented upon. These examples demonstrate howmolecular de-
sign and chemistry are successfully employed to create versatile multifunctional moleculeswhich self-assemble/
disassemble in a precisely predicted manner, thus controlling compartmentalization, transport and delivery.
Finally, we discuss whether recent advances in the design and preparation of supramolecular delivery systems
have been sufﬁcient to drive real translation towards a clinical impact.
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Less invasive therapies, that can mediate repair and regeneration of
a variety of damaged tissues and provide faster and more efﬁcient
healing responses, are currently major clinical targets. In response to
this pharmaceutical challenge, drug delivery systems have evolved tre-
mendously during the past years. Current research in the area is focused
on the development of multifunctional and stimuli-sensitive systems
that can perform multiple functions (simultaneously or sequentially)
and overcome diverse physiological barriers to optimize delivery to tar-
get sites (organs, tissues, cells) (Fig. 1A) [1].
Considering the importance of growth factors (GFs) in tissue regen-
eration, delivery of these molecules into damaged/degenerated tissues
has become an obvious strategy to enhance the healing process. Their
direct injection, or systematic local supplementation, results in lower
availability of the GFs because generally these molecules have a short
half-life in circulation (up to several minutes) due their rapid degrada-
tion in vivo [3,4]. On the other hand, tissues need to be exposed to gra-
dients of these proteins for considerable periods (long-acting) to obtain
robust regenerative responses. In vivo, this problem is solved by protec-
tion and stabilization of theGF via their binding to different extracellular
matrix (ECM) components. As a result, matrix-bound GFs are more ef-
fective than their soluble counterparts. In a similar manner, materials
designed to bind soluble GFs can be used to control protein concentra-
tion locally and regulate GF signalling. Inspired by the native environ-
ment of GFs, the ECM, researchers have proposed different self-
assembly approaches that mimic the supramolecular interactions
within the ECM for the design and development of sophisticated deliv-
ery systems with higher stability and speciﬁcity. Because self-assemblyFig. 1. Strategies formultiple drug delivery using distinct nanocarriers. (A)Multifunctional, stim
a particular tissue, to increase cell penetration, to enable imaging or to release the drugs in resp
micelles for targeted delivery. Lipopeptidemonomers with different functionalities X (I). The co
ligands (II) (adapted from [2]).can be triggered at a desired place and time, self-assembling carriers
offer a unique approach for the controlled release of bioactive and
therapeutic molecules. While self-assembled nanocarriers (micelles, li-
posomes, vesicles, tubes) have been widely used for the delivery of
small drugs [5], the supramolecular presentation of bioactive macro-
molecules such as proteins ismore challenging. The sequestering of spe-
ciﬁc or multiple proteins can be done by the integration of bioactive
molecular components that have selective or broad afﬁnity to the
targeted GFs into the self-assembling carriers. However, the incorpora-
tion of these functionalities into self-assembling carriers, and the subse-
quent binding of large molecules (e.g. proteins), may disturb their self-
assembly. In addition, integration of complex functionalities can lead
to difﬁculties in their synthesis, posing scale-up problems for manufac-
ture and translation into the clinic. Recognizing these challenges, re-
searchers have been using bioinspired designs to recreate the natural
extracellular environment for controlling the co-localization and release
of proteins.
In this review, we begin by introducing GFs relevant to bone regen-
eration and the role of the ECM in the control of GF signalling. We then
describe different carrier systems, inspired by the molecules and inter-
actions present in the ECM, with a special focus on peptide self-
assembly and polyelectrolyte complexation. We give a brief overview
on how these carriers can be engineered (through rational molecular
design) and manipulated (by changing their assembly environment)
to control the encapsulation and release of molecules of interest. The
purpose is to provide supramolecular elements for themolecular design
of carriers for GF delivery. Finally, we provide key examples of supramo-
lecular strategies that have been used to construct carriers and control
the release of GFs involved in bone regeneration.uli-responsive nanoparticles. Various agents can be integrated in the nanoparticle to target
onse to a given stimulus (adapted from [1]). (B) Self-assembled modular multifunctional
mbination of different monomers originates micelles with chemically deﬁnedmultivalent
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GFs are large polypeptides that modulate cellular activities such as
adhesion, proliferation, migration, differentiation and gene expres-
sion [6]. They are activated by binding to speciﬁc receptors on the sur-
face of target cells and the density of these receptors largely reﬂects
the cell response. GFs can either be found as bound proteins to the
ECM or as soluble molecules secreted by cells. The activity of bone
cells is modulated by several families of GFs (Table 1). Among them,
the cytokines BMP-2 and BMP-7 from the family of bonemorphogenetic
proteins (BMPs) have been approved by FDA and are used clinically.
INFUSE® Bone Graft is an US FDA approved commercially available car-
rier, based on a sponge of bovine collagen type I, used for the delivery of
recombinant human BMP-2 (rhBMP-2) to stimulate bone formation in
orthopaedic and dental applications. The carrier sponge localizes the
rhBMP-2 at the site of implantation and resorbs over time.
Delivery of GFs can either be done using the GF free within the car-
rier (physical entrapment) or bound to it through a covalent linkage
or non-covalent interactions. The selection of the immobilizationmeth-
od depends on the GF itself and/or the delivery strategy/application [6].
GF immobilizationmethods, aswell as their advantages and limitations,
have been described in several reviews [6–8].
3. Extracellular matrix (ECM) as a depot for GFs
The ECM is a unique structural support for organs and tissues as well
as for individual cell attachment, differentiation, proliferation and mi-
gration. It is well established that its mechanical properties inﬂuence
signiﬁcantly the cellular behaviour [20–22]. The role of the ECM, how-
ever, goes far beyond just being a simple supporting scaffold [23]: it pro-
vides signiﬁcant biochemical information displayed via the molecules
secreted by the cells, i.e. it is unique for each cell. Many soluble factors,
including GFs, are secreted by cells and entrapped in the ECM where
they are stored (stabilized and protected from denaturation and enzy-
matic degradation [24]), distributed and/or activated [23,25,26]. ECM
components are thus acting as local regulators of GF activity. Because
the ECM itself is a dynamic structure, all ECM–GFs interactions are
also dynamic, reversible and orchestrated by multivalent non-covalent
interactions.
3.1. Dynamics and signalling
Cells constantly remodel the ECM by degrading and reassembling it,
and this process is particularly intensive during tissue development and
healing [27]. During the remodelling process, the ECMchemical compo-
sition (degradation of ECM components such as proteins and glycans)
and physical properties (elasticity, stiffness, resilience of the cellular en-
vironment) are signiﬁcantly altered [28]. The remodelling of the ECM is
poorly understood as it is controlled by complex signal transduction
cascades involving many proteins, but it is well established that
integrins are crucial players in this process as they are the main mean
of communication between cells and their closest environment [29].
Glycosaminoglycans (GAGs) are other ECM components that are con-
stantly changing during the processes of differentiation and healing.
As an example, they play crucial role in the formation of stem cell
niches — speciﬁc microenvironments that save stem cells fromTable 1
Main families of GFs that are involved in bone development.
GF family Abbreviation Role in bone physiology
Fibroblast growth factors FGF Growth and patterning of the lim
Bone morphogenic proteins BMP Bone, limb and cartilage morpho
Vascular endothelial growth factors VEGF Critical role in bone formation by
Insulin-like growth factors IGF Most abundant GFs in the skelet
and bone resorption
Transforming growth factor-β TGF-β Tissue morphogenesis, cell prolifdepletion and protect the host from over-exuberant stem cell prolifera-
tion. Stem cell niches are distinguished by the presence of low sulfated
GAGs [30,31], whose role is to avoid exposure of stem cells to GF and re-
ceptor binding and thus to maintain them in undifferentiated state.
When daughter cells are translocated outside the niche, they are no lon-
ger protected by this shield and exposed to proteins that activate differ-
ent signalling pathways and hence compelling processes such as
proliferation and differentiation. Loss of pluripotency and differentia-
tion are accompanied with changes in the sulfation pattern of GAGs in
the ECM: drop in the level of non-sulfated disaccharides and increase
in the sulfation is observed upon differentiation of human stem cells
in different lineages [31].
3.2. Molecular recognition
Among the ECM components, proteins and their glycoconjugates
(proteoglycans and glycoproteins) are mostly involved in the interac-
tions with GFs [32,33]. Heparan sulfate proteoglycans (HSPG) are the
best studied pairs for GFs binding [34]. HS is a linear GAG that is nega-
tively charged due to the numerous sulfate groups along its backbone.
These sulfate groups serve asmultiple contacts to positively charged re-
gions in proteins andGFs (made up of clusters of basic amino acids). The
linear structures of GAGs restrict movement of bound proteins to one
dimension in the three-dimensional space, facilitating intercellular
communication (both paracrine and endocrine signalling) over these
molecular wires. The interactions between GFs and GAGs are speciﬁc,
involving formation of highly organized complexes of two or often
more than two macromolecules. An excellent example that illustrates
this orchestrated self-assembly process is the activation of basic ﬁbro-
blast growth factor (FGF-2) for which formation of a tight ternary com-
plex between theGF, HS and the receptor for the growth factor (FGFR) is
required (Fig. 2) [35–37]. FGF-2 alone has high afﬁnity to HS [36]: the
interaction occurs via the pentasaccharide (Fig. 2A) as soon as the GF
is secreted by the cells (Fig. 2B–I). As a result, FGF-2 is immobilized in
the ECM, near to the site of secretion, where it is stored and protected
against degradation until further use [24]. The activation of the stored
FGF-2 is done also by HS, but in this case a longer (10 mer) sequence
is required [38]. This longer sequence binds to both FGF-2 and FGFR in
a ternary complex (Fig. 2B-II). The obtainedminimal complex is further
stabilized by dimerization that is also promoted by HS (Fig. 2B-III). Be-
sides FGF, other bone-related GFs such as TGF-β [39], VEGF [40–42],
IGF [43,44] and/or their receptors also interact speciﬁcally with HSPG.
This review is focussed on biomimetic supramolecular (non-cova-
lent) interactions to build carriers from peptides and GAGs, and to con-
trol the binding and release of different GFs, recapitulating the function
of the ECM.
4. Supramolecular strategies for the controlled release of GFs using
peptides and glycosaminoglycans (GAGs)
Using self-assembly and a variety of building blocks (nucleotides,
saccharides, phospholipids, amino acids), Nature not only organizes
macromolecules into hierarchically ordered structures and tissues, but
also coordinates many molecular recognition processes. Peptide and
protein self-assembly is a well-studied phenomenon in chemistry and
biology, where their peptide chains self-associate into well-deﬁnedRef
b, bone homeostasis, differentiation of BMSC into osteoblasts [9–11]
genesis and development; involvement in the osteoblasts differentiation [12,13]
controlling the recruitment, survival and activity of bone forming cells [14,15]
al tissues; involved in osteoblasts proliferation, bone matrix synthesis [16–18]
eration and cell differentiation [19]
Fig. 2. Speciﬁc binding sites in HS for FGF-2 (A) and their interactions by forming self-organized complexes via electrostatic interactions that can protect the GF (B-I) or activate it (B-II
and III).
66 H.S. Azevedo, I. Pashkuleva / Advanced Drug Delivery Reviews 94 (2015) 63–76functional structures through non-covalent forces (electrostatic interac-
tions, hydrogen bonds, aromatic interactions, van der Waals forces and
hydrophobic effects). Self-assembly offers several advantages to devel-
op delivery carriers, such as simple route to fabricate complex systems,
ease of incorporating multiple active units, tunability of nanostructure
morphology and responsive nature. The reversibility of the assembly
process, i.e. the disassembly, is also a consequence of the involvement
of non-covalent interactions. As a result, self-assembly/disassembly
can be triggered by an external or internal trigger (pH, temperature, en-
zyme activity) in spatial conﬁnement. Thus, thismethodology offers the
possibility of incorporating different molecular guests (drugs, proteins)
during the process of self-assembly and their release can be controlled
through reversible structure transitions.
Beside proteins, othermain components of the ECMareGAGs,which
are native binding partners of GFs in the closest cellular environment.
Therefore, they have also attracted great attention as a building element
in self-assembling delivery systems [45,46]. GAGs are anionic polymers
whose charge is generally associatedwith the presence of sulfate groups
with only one exception — hyaluronic acid (hyaluronan, HA) in which
the charge is due to the presence of carboxylic groups in the glucuronic
acid sugar unit. Their negative charge is the main driving force for the
self-assembly with GFs that have basic isoelectric points (e.g. all BMPs,
TGF-β, FGF-2). Beside electrostatic interactions, hydrogen bonding can
be also involved in the stabilization of the formed GF–GAG complexes.
Delivery systems using GAGs as building blocks have several advan-
tages: (i) they can stabilize the GFs during the self-assembly process
and conﬁne them with proper folding/conformation; (ii) protect the
loaded GF from degradation; (iii) present minimal toxicity; (iv) offer
the possibility for target delivery and optimization of the release proﬁle.
4.1. Self-assembly approaches to design peptide-based carriers
Peptidemolecules have beenwidely used as delivery carriers as they
provide the possibility to form precise multivalent nanoarchitectures
(micelles, vesicles, tubes, Fig. 1B). In addition, speciﬁc peptide se-
quences, that are recognized by cell surface integrins/receptors or en-
zymes, can be integrated into the peptide structure and thus afford
further control of these modular assemblies to interact speciﬁcally and
selectively with cells or tissues. For example, modular multifunctional
micelles allow different functions to be incorporated into the same car-
rier (Fig. 1B). As such, peptide-based self-assembling systems (peptide
amphiphiles, cyclic peptides, surfactant-like peptides, aromatic dipep-
tides, dendritic peptides) have been extensively studied as carriers for
transport and delivery of different molecular drugs (oligonucleotides,
hydrophobic chemotherapeutics) [47–51] into desired parts of
the human body. Molecular design and manipulation of the environ-
mental conditions can be useful strategies for controlling the release
patterns of molecules of interest using these self-assembling peptide-based carriers. Most of the studies described below are fundamental
and do not report the use of GFs, but model molecules. However, this
class of carrier systems provides exquisite control over speciﬁc
functionalization and release of encapsulated molecules, which may
serve as a source of inspiration. Their inherent biocompatibility and bio-
degradability anticipate excellent prospects for their use in the con-
trolled delivery of bioactive proteins like GFs.
4.1.1. Molecular design
It is well known that the sequence of amino acids in peptides dic-
tates their secondary structure. Mutations of key amino acids, and/or
changes of their position in the primary structure, have an impact on
the intermolecular forces and dramatically change the morphology of
peptide assemblies. This ability has been explored for controlled release
applications.
Shi and colleagues [52] have developed choline mimicks (Ada-
GFFYKKK′, Nap-GFFYKKK, Ada — adamantine, Nap — naphthaline, G —
glycine, F — phenylalanine, Y — tyrosine, K — lysine, K’ — lysine deriva-
tive by its quaternization) and demonstrated that their self-assembly
can be directed into nanoparticles or nanoﬁbres by simple change
of the peptide capping group (Ada or Nap). Their study shows that
self-assembly strategies can yield nanostructures with controllable
multivalent architectures and anticipates the ability of these systems
to selectively interact with GFs, if functionalized with speciﬁc peptide
sequences (Table 2).
Zhao et al. [48] have shown that by changing the position of
phenylalanine (F) in RADA peptides (RADAFI: CH3CONH-RADARADAR
FRADARADA-CONH2, RADAFII: CH3CONH-RADFRADARARADARADA-
CONH2) different nanostructures are formed by self-assembly, from
twisted nanoﬁbres with varying diameter and length (RADAFI) to ﬂat
and uniform nanoﬁbres (RADAFII). Through π–π stacking, molecules
with phenyl groups can be entrapped into the peptide RADAF self-
assembled gels. The resulted distinct nanomorphologies play a role in
the release of L-phenylalanine. This study elegantly shows the utility
of supramolecular interactions for the incorporation of molecules with-
in a self-assembled gel. Similarly, these nanoﬁbres can contain speciﬁc
functional groups on their surface to tether or capture GFs of interest,
as described in Section 4.2.
Introduction of cysteine (C) residues into the hydrophobic domain
of a de novo amphiphilic peptide (SA2: CH3CONH-A2V2L3WE2-CO2H),
known to form nanosized vesicles under physiological conditions
(SA2C3: CH3CONH-ACVCLCLWE2-CO2H), has allowed the formation of
disulﬁde bridges and crosslinking of peptide vesicles for increasing
their stability in vivo. Reduction of disulﬁde bonds intracellularly may
assist the release of hydrophobic drugs.
A new type of self-assembling peptides for the delivery of molecular
drugs, known as drug amphiphiles (DA), has been proposed by Cui
and co-workers [53]. A typical DA combines a hydrophobic drug (e.g.
Table 2
Examples of peptide sequences with binding afﬁnity to GFs with relevance in bone regeneration for non-covalent immobilization and sustained release applications.
GF Binding peptide sequence Applications Ref.
bFGF or FGF-2 KRTGQYKL Derived from phage display
(KD = 122 nM, estimated by SPR)
PEG hydrogels functionalized with binding peptide to bFGF allowed its sustained release and induced
in vitro differentiation of PC12 pheochromocytoma cell line in a gel-cell transwell culture system.
[78–80]
BMP-2 TSPHVPY
Derived from phage display
(KD = 37 nM, estimated by SPR)
Self-assembled peptide gel with binding afﬁnity to BMP-2 allowed prolonged retention of the GF and
promoted superior spinal fusion rates in vivo (rat posterolateral lumbar intertransverse spinal fusion
model) relative to controls and reduced the required BMP-2 dose by 10-fold.
BMP-2 binding peptides were attached to dendrimers, covalently grafted to HA, for controlling the
release of BMP-2 from hydrogels. The binding peptides attenuated the release of BMP-2.
[77,81,82]
TGF-β1 HSNGLPL
Derived from phage display
(KD: not determined)
Self-assembled peptide gel containing a binding epitope to TGF-β1 allowed localization of the GF,
prolonged its release and enhanced cartilage regeneration in vivo (full thickness chondral defect in
rabbit model).
TGF-β1 binding peptides were attached to dendrimers, covalently grafted to HA, for controlling the
release of TGF-β1 from hydrogels. The binding peptides attenuated the release of TGF-β1.
[75,81,82]
FGF-2
TGF-β1
PAP4ISG3YRARPAK
Derived from ﬁbrinogen fragment
(Fg β31-47) critical for GF binding
(TGF-β1: KD = 56.6 nM; FGF-2:
KD = 53.0 nM, estimated by SPR
for Fg β15-66)
Incorporation of Fg β15–66 into a ﬁbrin-mimetic (PEG functionalized with integrin-binding and
protease cleavable sequences) matrix as GF-binding domain. In vivo delivery of FGF-2 and PIGF-2 in a
diabetic mouse model of impaired wound healing using the ﬁbrin-mimetic matrix led to faster wound
closure and increased development of granulation tissue.
[73,83]
HA — hyaluronan; PEG — poly(ethylene glycol); KD: dissociation constant; PIGF-2 — placenta growth factor-2.
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(VQIVYK) derived from the Tau protein, conjugated through a linker.
These amphiphilic molecules self-assemble into discrete ﬁlamentous
nanostructures (nanoﬁbres or nanotubes) that can act as self-
delivering drugs, i.e., without the need for additional carriers, allowing
the precise control of drug content by attaching one or more drug mol-
ecules. TheseDAs also allow high drug loading contents (23–41%). Since
most of the anticancer drugs need to be internalized by cells to exert
their cytotoxic effect, a reducible linker (disulfylbutyrate, a molecule
that breaks down in the presence of glutathione a reducing agent pres-
ent in the cytosol) has been incorporated between the hydrophobic
drug and the peptide segment, to allow intracellular drug release. As-
suming that the hydrophobic drug and the linker are buried in the
core of the ﬁlamentous nanostructures, the supramolecular morpholo-
gy of DAs provides protection from the external environment and a
mechanism for drug controlled release. In vitro toxicity experiments
with different cancer cell lines have revealed identical toxicity of the
synthesized DAs compared to free drug.
4.1.2. Engineering release patterns
Sequential release of multiple signals can be only achieved via strat-
egies that allow precise and differential release kinetics for individual
factors. There are many potential advantages of using self-assembled
peptide carriers as delivery systems. Using rational molecular design
(as described in Section 4.1.1), the release (diffusion kinetics) may be
initiated and controlled by structural transitions (shape and size) in-
duced by microenvironmental conditions, such as temperature, pH, di-
lution, reduction agents or enzyme activities.
4.1.2.1. Dilution-, temperature- and pH-mediated release. Peptides can
adopt different conformations and change their structure in response
to changes in concentration, pH or temperature. For example, cationic
dipeptides (NH3+-FF-CONH2·HCl) have been used to fabricate nano-
tubes to bind negatively charged nucleic acids [50]. These cationic di-
peptides self-assemble into nanotubes at physiological pH through
π–π stacking and hydrogen bonding, but upon dilution they rearrange
to form vesicles, probably as a result of electrostatic repulsion. Immobi-
lization of DNAhas been achieved through electrostatic interactions and
this bindingdoes not disturb the tubular nanostructure. Intracellular de-
livery of DNA has been demonstratedwithHeLa cells, mostly likely after
conversion into vesicles.
The triﬂuoracetate (TFA) salt of a peptide amphiphile (C15H31CONH-
KTTKS-CO2H) can assemble into nanotapes (20 °C) that at higher tem-
perature rearrange into micelles [54]. This transition can be used tocontrol the amount of molecules encapsulated within these nanostruc-
tures and also their release by a temperature change.
Golderberger and collaborators [55] have designed self-assembling
peptide amphiphiles (PAs) capable of undergoingmorphological transi-
tions within very narrow pH changes (tenths of a pH unit) existing
either as singlemolecules or sphericalmicelles under normal physiolog-
ical conditions (pH 7.4, in serum-like ionic conditions) or as nanoﬁbres
in acidic environment (pH 6.6). They have developed a PA design strat-
egy consisting of a ratio of one hydrophobic amino acid (I, F, V, Y) to four
glutamic acids (E) (C15H31CONH-IA3E4-CONH2, C15H31CONH-FA3E4-
CONH2, C15H31CONH-VA3E4-CONH2, C15H31CONH-YA3E4-CONH2) and
this ratio has been essential to enable the morphological transition
in a desired pH range (6.0–6.6). This transition is concentration-
dependent and by varying the amino acids in the β-sheet-forming re-
gion (XA3), the transition pH could be systematically tuned (propensity
for β-sheet formation: I N F N V N Y). They have further incorporated a
magnetic resonance imaging agent (Gd(DO3A)) at the PA C-terminus
and the molecule-to-nanoﬁbre transition is still observed, although
the pH transition is shifted to pH 5.7. Similarly, peptide sequences
with the ability to bind GFs (Table 2) could be incorporated at the PA
C-terminus to capture and retain a speciﬁc GF at the surface of the PA as-
semblies. This study demonstrates that slight changes in pH can induce
morphological transitions on self-assembled PAs molecularly designed
for precise pH tuning and this provides the possibility to control the re-
lease of bioactive molecules bound to these PAs.
4.1.2.2. Enzyme-mediated release.Matrixmetalloproteinases (MMPs) are
often overexpressed during tissue remodelling and in certain patholo-
gies (e.g. inﬂammation, cancer) and can cleave a variety of ECM pro-
teins. Because MMPs recognize speciﬁc amino acid sequences, this
property has been explored to design MMP-sensitive delivery systems.
Variations of the sequence GPX1G↓LX2G (where ↓ denotes the expected
cleavage site, X1 being preferentially alanine or leucine, X2 being prefer-
entially glycine), known to be sensitive to gelatinases (MMP-2/MMP-9)
cleavage, have been incorporated into self-assembling peptide-based
carriers for inducing structural transitions upon MMP-2/MMP-9 cleav-
age and mediating the release of anticancer drugs [47].
Ulijn and collaborators [56] have recently developed a MMP-9
triggered micelle to ﬁbre transitions for controlled release of doxorubi-
cin (anticancer drug). The peptide design consists of phenylacetyl-
FFAGLDD-CO2H. The PhAc-FFA is the ﬁbre-forming segment and pro-
vides a hydrophobic environment for drug entrapment. The dipeptide
GL is the MMP-9 cleavable sequence, while DD imparts a hydrophilic
character to the peptide favouring micelle formation. Upon cleavage
by MMP-9, the hydrophilic shell is removed from the initial peptide
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hydrophobic forces. Thus, morphological transition allows the entrap-
ment of hydrophobic drugs and a mean for their sustained release.
The release of liposome contents mediated by MMP-9 has been
proposed by Sarkar et al. [57]. They have incorporated collagen-
mimetic peptides containing a MMP-9 substrate (H2N-GPQGLAGQRG
IVGLOG-CO2H, H2N-GPQGIAGQR(GPO)4GG-CO2H, H2N-GPQGLAGQR
(GPP)4GG-CO2H, H2N-GPQGLAGQR(GPO)4GG-CO2H, H2N-G(GPO)4
GLAGQR(GPO)4GG-CO2H) into the liposomes so the triple helical pep-
tides are protruding from the surface of the liposomes for facile cleav-
age. The release of a dye from the liposomes occurs only in presence
of MMP-9 and not by other proteolytic enzymes, demonstrating the
speciﬁcity of the system. “Uncorking” of the liposomes by MMP-9 re-
sults in their content release. This system can be made sensitive to en-
zymes secreted during bone regeneration (e.g. alkaline phosphatase
expressed by osteoblasts); the release of the GFs encapsulated within
these liposomes can be triggered by these speciﬁc enzymes from the
surrounding environment.
In a different approach, Cui and collaborators explore the activity of
MMP-2 to degrade peptide cross-linkers (CH3CONH-K2YGPQGIAGQ
YK2-CONH2, CH3CONH-K2YIPVSLRSGYK2-CONH2) containing two sub-
strates toMMP-2 (GPQG↓IAGQ and IPVS↓LRSG), that stabilize supramo-
lecular peptide ﬁlaments [58]. Hydrogels of the cross-linked ﬁlaments
can be potentially used as carriers for protein delivery, whose release
would occur through the dissociation of peptide ﬁlaments upon degra-
dation of the peptide cross-linkers by MMP-2.
Other enzymes have also been used to trigger the release of drugs
from self-assembled peptide carriers. For example, Stupp and co-
workers have designed a peptide amphiphile (H2N-KRRASVAGK[C12]-
NH2) containing a consensus sequence (RRXSY, where X is any residue
and Y is a hydrophobic residue) that is the substrate of a protein kinase
A (PKA) [59]. Upon treatment with PKA, the PA becomes phosphorylat-
ed (phosphorylation of serine (S) residue) causing the disassembly of
the original self-assembled cylindrical structures. Subsequent treatment
with alkaline phosphatase enzyme, which cleaves the phosphate
groups, results in PA reassembly. Disassembly in the presence of PKA al-
lows the enzyme-triggered release of an encapsulated cancer drug.
The protease α-chymotrypsin has also been used to cleave the PA
C15H31CONH-KKFFVLK [60]. Two cleavage sites within the PA are identi-
ﬁed. The ﬁrst preferential cleavage site is between the two F residues and
leads to a higher abundance of both C15H31CONH-KKF and FVLK. The sec-
ond cleavage process occurs at the C terminus of the second F residue to
produce C15H31CONH-KKFF and VLK. While the C16-KKFFVLK PA forms
nanotubes, the C15H31CONH-KKF and C16-KKFF PAs both self-assemble
into spherical micelles. The change in nanostructure from C15H31CONH-
KKFFVLK to C15H31CONH-KKF and C15H31CONH-KKFF leads to macro-
scopic changes in sample appearance and this transition can be useful
for the delivery of bioactive molecules.
4.2. Self-assembly and peptide functionalization approaches to control re-
tention and presentation of GFs
The covalent immobilization of proteins into self-assembling
nanomaterials allows insertion of precise combinations of proteins
into supramolecular systems, as it has been reported recently by Collier
and co-workers [61]. They have proposed a multicomponent system,
made of self-assembling peptides and fusion proteins having a β-sheet
ﬁbrillizing domain, that upon mixing co-assemble into polypeptide
nanoﬁbres displaying precise combinations of protein ligands (Fig. 3A).
The strategy has allowed the integration of proteins with different bio-
physical properties (ﬂuorescent proteins, cutinase enzyme) into β-
sheet peptide nanoﬁbres and retention of their activity. Although this
strategy has not been used for the immobilization of GFs, the versatility
of the proposed approach may offer great potential for the presentation
and delivery of multiple GFs. In a different approach, Mercado et al.
[62] have reported the immobilization of BMP-2 on self-assemblednanoparticles (NPs). rhBMP-2 has been grafted to self-assembled
poly(lactide fumarate) (PLAF) or poly(lactide-co-glycolide fumarate)
(PLGF) and poly(lactide-co-ethylene oxide fumarate) (PLEOF) NPs
to investigate its release from the NPs and subsequent osteogenic
activity on bone marrow stromal cells. The PLAF and PLGF macromers
have been functionalized with N,N′-disuccinimidyl carbonate to obtain
succinimide-terminated macromers (PLAF-NHS, PLGF-NHS). After NP
self-assembly, rhBMP-2 has been attached to the NPs by reaction be-
tween the protein amino groups with succinimide groups in the NPs.
PLAF and PLGF are biodegradable polymers and the release of rhBMP-2
has been dominated by degradation/erosion of theNPs, resulting in a lin-
ear release in the ﬁrst 5 and 15 days, depending on NP formulation
(PLGF-NHS or PLAF-NHS, respectively). Furthermore, the system has
been able to preserve the protein conformation after release and induce
differentiation of osteoprogenitor cells. The proposed system can thus
provide localized and sustained delivery of BMP-2 at the bone regenera-
tion site.
Covalent immobilization of GFs enables a stable linkage, but requires
chemical coupling of the GF to the carrier material, whichmay interfere
with its activity. In addition, if cell signalling requires GF in its free
form, a mechanism for the GF release needs to be further implemented
(e.g. degradable/sensitive linker).
An alternative strategy for the non-covalent immobilization of pro-
teins on supramolecular assemblies has been proposed by Matsumura
et al. [63]. They have constructed biotinylated peptides consisting of
three parts: biotin, a linker and a β-sheet forming region (PKFKIIEFEP)
(Fig. 3B). They have shown that peptide nanotubes, resulting from the
self-assembly, could be decorated with proteins using the binding of
anti-biotin antibody to biotin groups displayed on the peptide tubes.
Similarly, different proteins could be immobilized on the surface of
these biotinylated nanotubes through streptavidin-conjugated proteins.
Using a similar approach,Miller et al. [64] have investigated the delivery
of IGF-1 and TGF-β1 adsorbed or tethered to self-assembled peptide
((KLDL)3) nanoﬁbres to stimulate the proteoglycan production by
chondrocytes. Tethering is achieved through biotin–streptavidin
bonds using biotinylated-CH3CONH-(KLDL)3-CONH2 and biotinylated-
IGF-1 complexed with streptavidin. This system has initially been pro-
posed for the local delivery of IGF-1 as therapy formyocardial infarction
[65] since it has been shown that this strategy does not prevent the self-
assembly of RAD16-II peptide (CH3CONH-RARADADARARADADA-
CONH2) into nanoﬁbres. Tethering GFs to the peptide nanoﬁbres has re-
sulted in increased retention and long-term delivery, but it does not
achieve the same bioactivity as soluble delivery, which indicates the im-
portance of protein presentation when designing delivery strategies.
Sustained delivery of platelet-derived growth factor (PDGF-BB) inside
the myocardium of rats has also been achieved using a self-assembled
RAD16-II peptide gel system [66]. Although these peptide nanoﬁbres
do not have any speciﬁc binding sequence for PDGF-BB, it has been pos-
tulated that their amphiphilic nature may provide binding through
weak molecular interactions.
As previously mentioned, different ECM components can bind GFs
and serve as a reservoir, while regulating their activation, synthesis,
and degradation [67]. Understanding these interactions is critical to
modulate GF activity in different ways and to rationally design carrier
systems for the spatiotemporal control of GF release and ensuring prop-
er cell regulation. Binding GFs with strong afﬁnity can alter their local
concentration, limit their mobility (retain activity while bound) and in-
hibit their uptake by surrounding cells.
Based on their ability to bind sulfated GAGs, various GFs (VEGF, FGF-
2, BMP-2) have been immobilized in different self-assembling
delivery carriers through the incorporation of heparin, heparin-like
molecules [68] or heparin-binding peptides [69–72]. The ability of
non-proteoglycan ECM proteins, like ﬁbronectin (FN) and ﬁbrin(ogen)
(Fg) to bind GFs has also been explored for GF delivery [73]. Hubbell's
group has demonstrated that certain FN (FN III12-14, consisting of 284
amino acids and also known as the FN heparin-binding domain II) and
Fig. 3. Strategies for the immobilization of proteins on self-assembled nanomaterials. (A) Integration of proteins into self-assembling peptide nanoﬁbres through a fusion protein with
ﬁbrillizing tail (adapted from [61]). (B) Biotinylated peptide nanotubes for protein binding and display. (I) Chemical structure of designed biotinylated peptides with linkers of different
hydrophobicity. (II) Self-assembly of biotinylated peptides into nanotubes and modiﬁcation with anti-biotin antibodies labelled with gold nanoparticles (adapted from [63]).
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from different families (PDGF, FGF, VEGF, TGF-β, BMP). They have fur-
ther used these fragments to functionalize synthetic hydrogels for GF
presentation and promoting tissue repair in vivo. This strategy has
been shown to promote wound and bone tissue healing [73]. An inter-
esting possibility to explore would be to use speciﬁc regions of these
fragments, known to be critical for GF binding (shorter sequences,
Table 2) so they could be easily incorporated into self-assembling
carriers. Simpler delivery systems may improve safety and cost-
effectiveness, and facilitate translation into the clinic.While co-delivery of several GFs is most likely required to build an
efﬁcient and proper regenerative environment, that fully control the
different phases of healing [8], the delivery of speciﬁc GFs at a pre-
determined time may require more selective binding strategies. A
possible strategy consists in using phage display to identify peptide se-
quences that bind speciﬁcally and selectively to GFs (Table 2). Peptides
with afﬁnities to a wide range of targets, including GFs, can be accessed
through the MimoDB database (freely available at http://immunet.cn/
mimodb [74]). Using a phage-derived peptide sequence with binding
afﬁnity to TGF-β1 (Table 2), Shah et al. [75] have designed a
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displaying an epitope for TGF-β1 (H2N-HSNGLPLG3SE3A3V3(K)-[C12]-
NH2, Fig. 4A-II). Peptide amphiphiles (PAs) are a class of molecules in
which a hydrophobic alkyl tail (Fig. 4A-I and II, black) is covalently
bound to a peptide segment that includes two or three distinct domains.
The sequence close to the alkyl tail is designed to have strongpropensity
to form intermolecular hydrogen bonding and originate β-sheets
(Fig. 4A-I and II, green). A second domain contains charged amino
acids (Fig. 4A-I-and II, red) for enhanced solubility in water and
allowing electrostatic screening. The third domain (Fig. 4A-II, blue) is
typically used for displaying bioactive signals at the nanoﬁbre surface,
as these molecules are known to self-assemble into high-aspect-ratio
cylindrical nanostructures. To allow ﬂexibility and extended presenta-
tion of the bioactive signal, a linker region (Fig. 4A-II, grey) is included
before the epitope domain.When mixed with TGF-β1, the supramolec-
ular system, in the form of self-assembled peptide gel, has been able to
retain and slow-down its release. The incorporation of TGF-β1 into
these peptide gels has also promoted the chondrogenic differentiation
of encapsulated stem cells, possibly to the interaction of TGF-β1 and
its receptors (Fig. 4B), and the regeneration of articular cartilage
in vivo (Table 2).
Using the same approach, the Stupp group has recently designed
a PA nanoﬁbre system with binding afﬁnity to BMP-2 (H2N-
TSPHVPYG3SE3A3V3(K)[C12]-NH2, Table 2) to create a self-assembled
gel for inducing osteogenesis in spinal fusion and to reduce the amount
of BMP-2 used clinically in these procedure [77]. When in solution, the
PA nanoﬁbres have induced the differentiation of C2C12 pre-myoblast
cells into osteoblasts through BMP-2 bound to the PA nanoﬁbres. In
vivo studies, using the BMP-2-binding nanoﬁbres in a translational
model of bone regeneration (Table 2), have shown that this system
allowed a 10-fold reduction in the BMP-2 dose to achieve 100% fusionFig. 4. (A) Chemical structure of PAs designed to formnanoﬁbers (I and II) and presenting bindin
display the GF for signalling (adapted from [75]). (B) Schematic depiction of TGF-β signalling (rate. This observed efﬁcacy has been explained by the ability of this
BMP-2-binding peptide nanoﬁbres to both capture exogenously deliv-
ered or endogenously expressed GF.
Immobilization of GFs by non-covalent interactions also offers the
possibility to better control their retention, distribution and release, by
tuning themolecular interactions (strong, moderate, weak). In this con-
text, a valuable tool consists in determining the association (Ka) and dis-
sociation (KD) constants between the GFs and speciﬁc functionalities in
the carrier system. Surface plasmon resonance (SPR), isothermal titra-
tion calorimety (ITC) and quartz crystal microbalance (QCM) have
been widely used to study macromolecular interactions. Delivery sys-
tems based on reversible afﬁnity mechanisms are an effective alterna-
tive to control the availability of GFs without the need of chemical
modiﬁcation of the protein. Table 2 lists peptide sequenceswith binding
afﬁnity to GFs with relevance in bone regeneration. Through molecular
design, afﬁnity and release of GFs can be engineered to regulate cell
signalling.
4.3. Polyelectrolyte complexation approaches to design GAG-based carriers
Interpolyelectrolyte complexation (IPEC, Fig. 5) is the easiest encap-
sulation method for delivery of charged biomacromolecules because
simple mixing with a carrier bearing opposite charge leads to self-
assembly. The simplicity of themethod, together with the predictability
of the generated structures and the possibility to perform the complex-
ation in aqueous solutions at or near physiological pH and ionic
strength, make this method a preferable approach for delivery of sensi-
tive therapeutics such as proteins.
In fact, the feasibility of polysaccharide-based IPECs has been already
demonstrated in the ﬁeld of bioengineering as this is themost common
method for gene delivery: the phosphate groups of RNA and DNAg epitopes to TGF-β (II). Co-assembly of both PAs generates nanoﬁbres able to capture and
adapted from [76]).
Fig. 5. Schematic representation of interpolyelectrolyte complexation. At low ionic strength, the complexation is entropy-driven by the release of small counterions, initially bound to the
polyelectrolytes. The polyions assemble into highly ordered (ladder-like) or disordered (scramble egg) structures.
71H.S. Azevedo, I. Pashkuleva / Advanced Drug Delivery Reviews 94 (2015) 63–76(strong negative charge) readily interact with polyamines, such as chi-
tosan, leading to the formation of complexes (so-called polyplexes)
that are stable under physiological conditions [84]. Proteins, however,
differ from the nucleotides by their lower charge density. The current
approaches targeting stabilization of protein IPECs can be divided in
two main groups: (i) IPEC that involve the use of additional polycation
(most of the GFs in Table 1 have basic pI and thus in IPEC they are acting
as polycations) usually chitosan and (ii) IPEC involving polyanions that
have been additionally functionalized (most often sulfated) in order to
present higher negative charge. In any of these approaches, the condi-
tions for the formation of stable complexes must be optimized. Several
parameters, such as mixing regime, medium conditions and macromo-
lecular characteristics of the polyelectrolytes are decisive for the forma-
tion, morphology and stability of the complexes, as IPEC is a very fast
(less than 5 μs [85]), mainly kinetically driven process.
4.3.1. Mixing regime
The ﬁrst step in the preparation of polyelectrolyte complexes (PECs)
is the determination of the stoichiometry of the ionic binding, i.e. the
charge ratio between the polyions that will lead to shift in the equilibri-
um (Fig. 5). There are several techniques that can be used for this pur-
pose, among which turbidity [86,87] and the electrophoretic light
scattering [88–90] are the most common ones. Using these two tech-
niques, and quite dilute water solutions of polyelectrolytes (below
1 × 10−3 g/mL) it has been demonstrated that stable complexes are
formed in an excess of one of the polyions. The obtained complexes
comprise a neutral core surrounded by stabilizing charged shell that is
built from the excess component [86,88] (Fig. 6). This behaviour has
been observed for heparin that is a strong polyanion, but also for HA
which is a typical weak polyanion [88]. Different cellular compartments
can be targeted by selecting the mixing ratio between the polyions:
when the polycation is in an excess, an overall positive charge of the
complex is expected and thus, cytoplasm and mitochondria will be the
targeted compartment. Lysosomes are targeted by anionic nanoparti-
cles, i.e. in the case of an excess of the polyanion [91].
The GF can be incorporated in the PEC during the assembly process
(usually as a polycation that is in deﬁcit) [89,90,92] or after the PEC
has been already formed by its incorporation in the charged stabilizing
shell [93] (Fig. 6). The former approach offers superior control over
the encapsulation efﬁciency and better protection of the GF againstenvironmental stress conditions. The stabilizing shell is not formed
when a stoichiometric charge ratio is used (1:1). In this case, the obtain-
ed complexes are hydrophobic because of the mutual screening of the
charges and as a result secondary aggregation/ﬂocculation occurs [86].
Schatz et al. have demonstrated that this ﬂocculation is irreversible
when polysaccharides are used as polyions (Table 3), i.e. it cannot be
avoided by following addition of large excess of one of the polyions,
most probably because of the strong electrostatic interactions
(ΔpKa ~ 4.5) already established between the polyions, but also as a re-
sult of the numerous H-bonding occurring between the polysaccharides
(chitosan as a polycation and GAGs as polyanions). The rate of the poly-
electrolytes mixing does not inﬂuence signiﬁcantly the assembly pro-
cess: one-shot additions of polyelectrolytes or slow dropwise
supplement result in complexes with the same properties [86]. In fact,
this is an expected result, since the IPEC is a fast, kinetically-driven
process.
4.3.2. Macromolecular characteristics of the polyelectrolytes
Molecularweight, charge density and chain stiffness of the polyelec-
trolytes are the main properties that can inﬂuence the assembly pro-
cess. It has been demonstrated that the molecular weight determines
the size of the formed complex for polysaccharides [99]. Because
polysaccharides have relatively stiff conformations, one can assume
that the use of polysaccharides with high molecular weight will
result in the formation of amore swollen core and thus, in larger assem-
blies. However, this behaviour is not always observed. For example,
Huang et al. have studied several polycations with similar molecular
weights in combination with dextran sulfate for VEGF delivery [90].
They have found that the size of the formed complexes is dependent
of the charge density of the polycations and the diameter of the formed
complexes decreased in the following order: chitosan (284 ± 4) N
polyethyleneimine (258 ± 14) N poly-L-lysine (159 ± 3). These PECs
have showndifferent encapsulation efﬁciencybut in all cases a stabiliza-
tion effect of dextran sulfate over VEGF secondary structure has been
observed. This effective stabilization has resulted in an increased prolif-
eration of human umbilical vein endothelial cells when compared with
the negligible effect of the free supplemented GF. Charge density is also
important for the stability (assembly/disassembly equilibrium) of the
PEC. Recent studies with different GAGs have demonstrated that HA
and poly-L-lysine (PLL) do not form PECs that are stable at physiological
Fig. 6. Formation of colloidally stable polyelectrolyte complexes: when an excess of the polyanion (green) is used, assemblies with negatively charged shell are formed (left); if the
polycation (blue) is in excess, the shell is with positive charge (right). GFs can be incorporated during the assembling or after the complex has been formed.
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charge) the stability of these complexes is signiﬁcantly improved [89].
4.3.3. Medium conditions
Interpolyelectrolyte complexes are responsive systems sensitive to
changes in their environment. The stability of the complexes in water
or in culturemedia (abundant of other proteins and salts) is quite differ-
ent. The presence of small amount of sodium chloride (NaCl) alone can
lead to dramatic changes in the aggregation and stability of the com-
plexes. Upon addition of small amount of salt, an initial swelling is
typically observed for complexes that have been formed by weak poly-
electrolytes in pure water. This swelling state facilitates polyions ex-
change and substitution reactions in media with higher ionic strength
and/or presence of components with high molecular weight or higher
charge density. Increasing quantity of salt can lead to complex disrup-
tion at so called critical salt concentration. This concentration is charac-
teristic for each PEC and depends on the charge densities of polyions, as
already discussed above.
4.3.4. Release of the encapsulated GFs
Carriers providing a controllable release proﬁle that meets the tem-
poral and spatial demands of regenerating tissue are of upmostTable 3
Examples of natural polysaccharides used as polyanions in the design of PECs nanoassemblies
GF (polycation) Polysaccharide (polyanion) Additional polycation Obse
FGF-2 Heparin poly(argininate glyceryl succinate) Vascu
FGF-2 Heparin Chitosan Incre
FGF-2 Chondroitin sulfate Chitosan Incre
FGF-10 Dextran sulfate Chitosan, PLL Enha
VEGF Dextran sulfate Chitosan, PLL Incre
VEGF Heparin Chitosan Incre
Platelet lysates Chondroitin sulfate Chitosan Osteo
ECs — endothelial cells; HUVECs — human umbilical vein ECs; PLL — poly-L-lysineimportance in the design of GF delivery systems. So far, several different
strategies for tailoring the release characteristics of PEC have been re-
ported. Chen et al. have demonstrated that by adjusting the mixing
ratio between dextran sulfate and chitosan, the release rate of the
encapsulated biomolecule can be controlled [101]. Lee et al. have
developed dual-loaded heparin-based micelles by using different en-
capsulation methods for each of the bioactive agents (Fig. 6). While in-
domethacin was loaded into the core of the complex, the FGF-2 was
incorporated into its outer shell [102]. Contrary to what would be ex-
pected (faster release of FGF-2 against indomethacin), more sustained
release of the GF is observed. The authors explained this unexpected be-
haviour by the favourable ionic binding of FGF-2 to heparin, as com-
pared with the hydrophobic interactions that keep the indomethacin
in the inner core of the complex. Selecting polyions with proper macro-
molecular characteristics can also be used to tailor the release proﬁle via
controlled degradation/disassembly of the PEC and physiological diffu-
sivity. Zern et al. have shown that FGF-2 is released slower from heparin
based PEC when an additional polycation with lower molecular weight
is used (20% release of the encapsulated GF for 1 month), while the PEC
formedwith highmolecular weight polycations releases approximately
50% of incorporated GF over the same period of time [94]. Another pos-
sible release mechanism is related with the biodegradability of the usedfor delivery of GFs.
rved effect Ref
larisation [94,95]
ased marrow stem cells proliferation [96]
ased marrow stem cells proliferation [96]
nced proliferation of ECs [97]
ased HUVECs proliferation [90]
ased extracellular matrix production and accelerated vascularization in vivo [98]
genic differentiation of adipose derived stem cells [93]
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expressed during diseased states (e.g. hyaluronidase is overexpressed
in patients with rheumatoid arthritis) and thus they are an excellent ex-
ample of responsive polyanions that can release the encapsulated bioac-
tive agent under these conditions.
4.3.5. Micellar delivery systems based on block co-polymers
The physicochemical properties of GF carriers, their size and size dis-
tribution, aswell as their surface charge, determine the in vivo fate of the
delivered GF. The described above PECs need to be charged in order to
confer them colloidal stability. However, a charged carrier is not always
the best one in terms of delivery strategy, as it is very likely that it can
interact non-speciﬁcally with proteins under physiological conditions
before reaching the targeted site. Some years ago, Kataoka et al. has pro-
posed the use of block copolymermicelles as delivery vehicles aiming to
overcome this drawback [104]. The delivery systems based on block co-
polymers present several advantages over other polymeric release sys-
tems: sizes smaller than 200 nm (particles with larger size are easily
uptaken from the reticuloendothelial system and rapid clearance from
the circulation [105]), superior control over the nanostructure assembly
and release proﬁle, tissue penetrating ability, reduced toxicity among
others [89]. They are assembled uponmixing of stoichiometric amounts
of two polyelectrolytes, one (or both) of which is covalently attached to
another hydrophilic non-ionic segment that itself does not participate in
the complexation process (Fig. 7). As a result, the formedmicellar struc-
ture comprises a PEC inner core that act as a molecular reservoir and a
neutral (most often PEG) shell that confer colloidal stability to the
nanocarrier and delay phagocytosis by prolonging the blood circulation
time (stealth effect). These properties are of upmost importance in the
case of GF delivery for bone regeneration,where a time-delay and stable
controlled release with little initial burst is desirable, while the carrier
manoeuvres the complex intricacies of bone structure to reach to the
diseased site [106]. Moreover, the small size of the vehicles allows direct
endocytosis and thus, the encapsulated protein can be released either
outside or inside the targeted cell, allowing achievement of the desired
effect by using smaller amounts of protein [91].
Such core-corona structures have been known for synthetic block
copolymers for several years [107,108] and have been applied for DNA
delivery [109]. Recently, GAG-b-PEG copolymers have been described
[89,100,110] and it has been demonstrated that they can be used for en-
capsulation of FGF-2 [89]. Themain challenge in this approach is to bindFig. 7. Schematic representation of the self-assembly between block copolymers and proteins.
environment by a neutral shell. Adapted from [89].the GAG polyanion to the PEG without altering its bioactivity. Oxime
click chemistry and binding via the reductive end of the GAG has been
proposed as a feasible approach for this synthesis [110]. The ﬁrst trial
with HA-b-PEG and PLL has demonstrated that complexes are formed
at low ionic strength, but when physiological value is reached the
formed complexes disassemble [100]. In follow-up studies, block copol-
ymers with larger negative charge have been used and as a result the
stability of the complexes was improved [89]. Moreover, it has been
demonstrated that the size of the formed complexes also depends on
the charge of the ionic component in the copolymer: higher charge den-
sity resulted in smaller complexes.
The future challenge in the ﬁeld involves the assembly of block co-
polymers with different non-ionic segments (Fig. 8). Such complexes
have been already realized for synthetic polymers. Functionalization of
the PEG free end with short targeting agent must lead to more efﬁcient
delivery strategies.
5. Conclusions and outlook
Learning from Nature is a constant challenge: processes and proper-
ties in Nature, which have been optimized overmillions of years of evo-
lution, are giving us inspiration to develop novel functional biodevices.
In the fast developing ﬁeld of targeted controlled delivery, scientists
have made several crucial technological advances in the past few
years that have facilitated to overcome at least some of the obstacles re-
lated to the design and further exploitation of responsive delivery sys-
tems. The power of supramolecular forces to develop dynamic self-
assembling carriers, that are programmed to form compartments for
therapeutics and change shape and size in response to subtle environ-
mental switches, offers great potential to deliver bioactive proteins for
tissue regeneration. A major promise of these carrier systems is their
potential to be tuned in a way that reversible transitions can be made
into their assembly state/morphology but also their afﬁnity can be
engineered. Although self-assembling carriers have shown great prom-
ise for the delivery of small drugs, larger molecules like GFs pose addi-
tional challenges. To fully exploit these systems in regenerative
medicine applications, further efforts should be devoted to dissect the
interactions that control GF binding and release, and identify the critical
elements to construct simpliﬁed ECM surrogates. In addition, many of
these self-assembled carriers remain as a proof-of-concept since their
design and properties require further optimization. Application ofThe formed nanocarriers have a molecular container core that is separated from the outer
Fig. 8. Schematic representation of interpolyelectrolyte complexation between block copolymers with different non-ionic segments. Adapted from [111].
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namics and computational modelling, to self-assembled carriers is nec-
essary to obtain insights into the interactions involved in the assembly/
disassembly and design carriers with optimized properties (enhanced
stability and higher delivery efﬁciency). This is especially important
for clinical applications where carriers with predictable properties are
required. Such devices will not only advance the ﬁeld of controlled re-
lease systems, butwill also enable the development of a newgeneration
of in vitro systems mimicking multiple aspects of living tissues.
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